(Q37950522)

English

Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer (English)

1 reference

Europe PubMed Central

25 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Sohita Dhillon

1 reference

Europe PubMed Central

25 August 2017

author name string

Katherine F Croom

1

1 reference

Europe PubMed Central

25 August 2017

publication date

1 November 2011

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

71

1 reference

Europe PubMed Central

25 August 2017

16

1 reference

Europe PubMed Central

25 August 2017

2213-2229

1 reference

Europe PubMed Central

25 August 2017

https://scigraph.springernature.com/pub.10.2165/11207720-000000000-00000

0 references

Global cancer statistics

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Antiangiogenic therapy for metastatic breast cancer: current status and future directions

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Bevacizumab: in first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Is breast cancer survival improving?

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Breast cancer with synchronous metastases: trends in survival during a 14-year period

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Third consensus on medical treatment of metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Triple-negative breast cancer: epidemiology and management options

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

1 reference

https://api.crossref.org/works/10.2165%2F11207720-000000000-00000

21 January 2018

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab improves the delivery and efficacy of paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complexation of VEGF with bevacizumab decreases VEGF clearance in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22035518

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11207720-000000000-00000

1 reference

Europe PubMed Central

25 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37950522&oldid=2088619915"